Tyrosine kinase inhibitor toxicity in the treatment of non-small-cell lung cancer: A bibliometric analysis (2009–2025)
Optimizing NSCLC therapy with TKIs requires proactive toxicity monitoring and integration of predictive biomarkers and real-world evidence to enhance efficacy and patient safety.
Authors
- Yerbolat Maratovich Iztleuov
- Aigerim Balapasheva (ORCID: https://orcid.org/0000-0001-9482-8965)
- L. BALYMBETOVA (ORCID: https://orcid.org/0000-0003-0430-1807)
- S. KOZHANTAYEVA (ORCID: https://orcid.org/0000-0002-0184-2440)
- Elnara Kereevna Ismagulova
Institutions
- West Kazakhstan Marat Ospanov State Medical University (KZ)
Publication Details
- Journal
- Medicine
- Published
- 2026-02-27
- DOI
- https://doi.org/10.1097/md.0000000000047860
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00